Clinical management of PCOS

References

• Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998; 27 (4): 877–902.
   Google Scholar
• Kidson W Polycystic ovary syndrome: a new direction in treatment. Med J Aust 1998; 169: 537–40.
   Google Scholar
• Ovesen PG, Moller N, Greisen S, Ingerslev HJ. Polycystic ovary syndrome I. Clinical presentation and treatment. Ugeskr Laeger 1998; 160 (3): 260–4.
   Google Scholar
• Futterweit W Polycystic ovary syndrome: Clinical perspectives and management. Obstet Gynecol Surv 1999; 54 (6): 403–13.
   Google Scholar
• Franks S, Gharani N, Waterworth D, Batty S, White D, Williamson R et al. Genetics of polycystic ovary syndrome. Mol Cell Endocrinol 1998; 145: 123–8.
   Google Scholar
• Franks S, White D, Gilling-Smith C, Carey A, Waterworth D, Williamson R. Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha. Baillieres Clin Endocrinol Metab 1996; 10 (2): 193–203.
   Google Scholar
• Legro RS. Polycystic ovary syndrome: Current and future treatment paradigms. Am J Obstet Gynecol 1998; 179 (6): S101–7.
   Google Scholar
• Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985; 61 (5): 946–51.
   Google Scholar
• Conway GS, Agrawal R, Betteridge DJ, Jacobs HS. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf 1992; 37 (2): 119–25.
   Google Scholar
• Wild RA. Obesity, lipids, cardiovascular risk, and androgen excess. Am J Med 1995; 98: 27S–32S.
   Google Scholar
• Talbott E, Guzick D, clerici A, Berga S, Detre K, Weimer K et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995; 15 (7): 821–6.
   Google Scholar
• Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 844: 1470–4.
   Google Scholar
• Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin insensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1995; 80: 2586–93.
   Google Scholar
• Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. HumReprod 1996; 11: 1884–91.
   Google Scholar
• Berga SL. The obstetrician-gynecologist’s role in the practical management of polycystic ovary syndrome. Am J Obstet Gynecol 1998; 179: S109–13.
   Google Scholar
• Armar NA, McGarrigle HH, Honour J, Holownia P, Jacobs HS, Lachelin GC. Laparoscopic ovarian diathermy in the management of anovulatory infertility in women with polycystic ovaries: endocrine changes and clinical outcome. Fertil Steril 1990; 53 (1): 45–9.
   Google Scholar
• Godsland IF, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992; 74: 64–70.
   Google Scholar
• Nader S, Riad-Gabriel M, Saad M. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997; 82: 3074–7.
   Google Scholar
• Hickey M, Higham J, Fraser IS. Progestagens versus oestrogens and progestagens for irregular uterine bleeding associated with anovulation. The Cochrane Library 2000: Issue 1.
   Google Scholar
• Eden JA. The polycystic ovary syndrome presenting as resistant acne successfully treated with cyproterone acetate. Med J Aust 1991; 155 (10): 677–80.
   Google Scholar
• Fruzetti F Treatment of hirsutism. Antiandrogen and 5al- pha-reductase inhibitor therapy. In: Azziz R, Nestler JE, Dewailly D (eds.): Androgen Excess Disorders in Women. Philadephia: Lippincott-Raven Publishers, 1997: pp. 787–97.
   Google Scholar
• Lee O, Farquhar C, Toomath R, Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. The Cochrane Library 2000: Issue 1.
   Google Scholar
• Rabe T, Grunwald K, Feldmann K, Runnebaum B. Treatment of hyperandrogenism in women. Gynecol Endocrinol 1996; 10: 1–44.
   Google Scholar
• Pucci E, Genazzani AD, Monzani F, Lippi F, Angelini F, Gargani I et al. Prolonged treatment of hirsutism with flutamide alone in patients affected by polycystic ovary syndrome. Gynecol Endocrinol 1995; 9 (3): 221–8.
   Google Scholar
• Paoletti AM, Cagnacci A, Orru M, Ajossa S, Guerriero S, Melis G. Treatment with flutamide improves hyperinsulinemic women with idiopathic hirsutism. Fertil Steril 1999; 72 (3): 448–53.
   Google Scholar
• Wong IL, Morris RS, Chang L. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80: 233–8.
   Google Scholar
• Filicori M, Flamigni C, Campaniello E, Meriggiola MC, Michelacci L, Valdon A et al. Polycystic ovary syndrome: abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing analogues. Am J Obstet Gynecol 1990; 163: 1737–42.
   Google Scholar
• Lemay A, Faure N. Sequential estrogen-progestin addition to gonadotropin releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism: a pilot study. J Clin Endocrinol Metab 1994; 79: 1716–22.
   Google Scholar
• Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson PO. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum Reprod 1998; 13 (10): 2706–11.
   Google Scholar
• Creatsas G, Hassan E, Deligeoroglou E, Tolis G, Aravantinos D. Treatment of polycystic ovarian disease during adolescence with ethinylestradiol/cyproterone acetate versus a D-Tr-6-LHRH Analogue. Int J Gynaecol Obstet 1993; 42: 147–53.
   Google Scholar
• Pugeat M, Ducluzeau PH. Insulin resistance, polycystic ovary syndrome and metformin. Drugs 1999; 58 (Suppl 1): 41–6.
   Google Scholar
• Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D et al. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000; 85 (8): 2767–74.
   Google Scholar
• Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82: 4075–9.
   Google Scholar
• Diamanti-Kandarakis E, Kouli C, Tsianateli T. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138: 269–74.
   Google Scholar
• Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet Gynecol 1997; 90: 392–5.
   Google Scholar
• Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure while facilitating normal menses and pregnancy. Metabolism 1994; 43 (5): 647–54.
   Google Scholar
• Morin-Papuen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998; 69: 691–6.
   Google Scholar
• Mantzoros CS, Dunaif A, Flier JS. Leptin concentrations in the polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 1687–91.
   Google Scholar
• Dunaif A, Scott D, Finegood D. The insulin-sensitising agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996; 81: 3299–306.
   Google Scholar
• Ehrmann D, Schneider D, Sober B, Cavaghan M, Imperial J, Rosenfield R. Troglitazone improves defects in insulin action, insulin secretion, ovarian steriodogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82: 108–16.
   Google Scholar
• Sattar N, Hopkinson Z, Greer I. Insulin-sensitising agents in polycystic ovary syndrome. Lancet 1998; 351: 305–7.
   Google Scholar
• White MC, Turner EI. Polycystic ovary syndrome : 2. Diagnosis and management. Br J Hosp Med 1994; 51 (7): 349–52.
   Google Scholar
• Shoham Z, Patel A, Jacobs MS. Polycystic ovarian syndrome: safety and effectiveness of step and lower dose administration of purified follicle-stimulating hormone. Fertil Steril 1991; 55: 1051–6.
   Google Scholar
• Hughes E, Collins J, Vandekerckhove P Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene resistance polycystic ovary syndrome. The Cochrane Library 2000: Issue 1.
   Google Scholar
• Greenblatt E, Casper RF. Endocrine changes after laparoscopic ovarian cautery in polycystic ovarian syndrome. Am J Obstet Gynecol 1987; 156 (2): 279–85.
   Google Scholar
• Gjonnaess H. A simple treatment for polycystic ovarian syndrome. World Health Forum 1990; 11 (2): 214–17.
   Google Scholar
• Farquhar C, Vandekerckhove P, Arnot M, Lilford R. Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. The Cochrane Library 2000: Issue 1.
   Google Scholar